Seneca Therapeutics
Seneca, a biotech company, innovates oncolytic immunotherapies for cancer treatment.
Founded
2018Seneca, a biotech company, innovates oncolytic immunotherapies for cancer treatment.
Seneca Therapeutics, founded with the mission to revolutionize cancer treatment, is a biotechnology company dedicated to developing novel oncolytic immunotherapies. Their core vision is to find a cure for cancer within our lifetime, working urgently towards this goal. Seneca's primary focus is on creating innovative therapies that harness the body's immune system to target and destroy cancer cells, offering a promising new approach in oncology.
Notable figures affiliated with Seneca Therapeutics include leading scientists and industry experts in biotechnology and oncology. The company has secured significant investments from prominent venture capital firms and has formed strategic partnerships with academic institutions to advance their research. Key achievements include the development of a robust pipeline of therapeutic candidates and the publication of groundbreaking scientific research. Seneca's impact lies in its potential to transform cancer treatment, offering hope to millions of patients worldwide.
Companies similar to Seneca Therapeutics include PineTree Therapeutics, Checkpoint Therapeutics, Novasenta and Fuse Biotherapeutics.
Seneca Therapeutics was founded in 2018.
Seneca Therapeutics' headquarters is located in Blue Bell, PA, US.
Seneca Therapeutics' most recent funding round was for $7.7M (USD) in January 2023.
As of Jan 5, 2023, Seneca Therapeutics has disclosed funding of $7.7M (USD). Undisclosed round amounts are excluded.
Seneca Therapeutics has 7 employees as of Feb 5, 2024.
Fuse Biotherapeutics
fusebiotx.com
